Segment Information (Details) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
segment
|
Jun. 30, 2024
USD ($)
|
|
| Segment Information | ||||
| Number of operating segments | segment | 1 | |||
| Revenue | $ 2,733,000 | $ 57,000 | $ 2,790,000 | $ 113,000 |
| Acquired in-process research and development | 117,464,000 | 117,464,000 | ||
| General and administrative expenses: | ||||
| Total general and administrative | 1,691,000 | 1,977,000 | 4,445,000 | 5,333,000 |
| Change in fair value of warrant liability | (146,000) | (26,659,000) | ||
| Other income, net | (188,000) | (205,000) | (368,000) | (434,000) |
| Net (loss) income | (915,000) | (123,143,000) | 20,575,000 | (128,126,000) |
| Single reportable segment | ||||
| Segment Information | ||||
| Revenue | 2,733,000 | 57,000 | 2,790,000 | 113,000 |
| Acquired in-process research and development | 117,464,000 | 117,464,000 | ||
| Research and development expenses: | ||||
| Preclinical and clinical development | 1,897,475 | 624,000 | 2,524,475 | 1,333,000 |
| Personnel related | 425,000 | 1,306,000 | 890,000 | 1,979,000 |
| Other research and development | 2,034,000 | 1,382,525 | 2,564,000 | |
| Other research and development | (31,475) | |||
| Total research and development expenses | 2,291,000 | 3,964,000 | 4,797,000 | 5,876,000 |
| General and administrative expenses: | ||||
| Professional and consulting fees | 634,000 | 5,000 | 1,826,000 | 2,083,000 |
| Personnel related | 512,000 | 1,120,000 | 1,416,000 | 1,892,000 |
| Other general and administrative | 545,000 | 852,000 | 1,203,000 | 1,358,000 |
| Total general and administrative | 1,691,000 | 1,977,000 | 4,445,000 | 5,333,000 |
| Change in fair value of warrant liability | (146,000) | (26,659,000) | ||
| Other income, net | (188,000) | (205,000) | (368,000) | (434,000) |
| Net (loss) income | $ (915,000) | $ (123,143,000) | $ 20,575,000 | $ (128,126,000) |
| X | ||||||||||
- Definition The amount of personnel expense incurred during the period included in research and development expense. No definition available.
|
| X | ||||||||||
- Definition Research and development expense during the period related to the preclinical and clinical development cost. No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|